Compounded Semaglutide vs Ozempic and Wegovy: What's Actually Different

Published Jun 2, 2026Updated Jun 2, 2026Last reviewed Jun 2, 2026

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last updated: May 2026

Last December, a woman named Rachel in suburban Phoenix called her endocrinologist's office with a question that sounded simple. She'd been on Wegovy for nine months, lost 38 pounds, felt better than she had in a decade, and her insurance was dropping coverage in January. The pharmacy quoted her $1,349 a month cash. A Wegovy coupon through the manufacturer's savings program knocked it down to about $500, but she didn't qualify because she'd been on the drug longer than the promotional window allowed. "So what do I actually do?" she asked the nurse on the phone. "Is the compounded version the same thing, or am I settling?"

That question, or some version of it, is now the most common one in weight-management medicine. And it's the one most often answered badly online, usually by someone selling one product or the other.

The honest answer: compounded semaglutide and branded Wegovy share an active ingredient. They do not share a regulatory status, a manufacturing chain, a finished formulation, or a body of clinical trial data tied to the specific preparation a patient holds in their hand. Those overlaps and those gaps both matter. How much they matter depends on your situation.

For background on what compounded semaglutide is and how it's dispensed, see the pillar guide.

Same Molecule, Full Stop

Ozempic, Wegovy, and compounded semaglutide all contain semaglutide. It's a GLP-1 receptor agonist developed and patented by Novo Nordisk. One molecule with a well-characterized structure and a well-characterized pharmacology.

When the same active ingredient hits the same receptors at the same dose via the same route, the pharmacological effect is the same. That's the principle that makes compounding legal in the first place. The compounded preparation is not a different drug. It's the same drug in a different finished form.

This matters. It's accurate. It's also not the whole story, and anyone who stops the explanation here is leaving out important context.

Where the Two Products Diverge

Ozempic and Wegovy are FDA-approved finished products manufactured by Novo Nordisk in tightly controlled facilities under current Good Manufacturing Practice (cGMP) regulations. Every batch gets tested for identity, purity, potency, sterility, and bioavailability against specifications on file with the FDA. The finished products ship in pre-filled pens with specific excipients (sodium acetate trihydrate, propylene glycol, phenol, sodium chloride, water for injection in Ozempic; a similar profile in Wegovy).

Compounded semaglutide is prepared by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities. The active pharmaceutical ingredient (API) comes from a registered supplier. The compounding pharmacy combines that API with appropriate excipients and prepares a sterile finished product under USP 797 standards. It ships in vials, typically at a concentration matched to the prescription, and patients draw doses with a separately supplied syringe.

Think of it like this: if Wegovy is a factory-bottled bourbon with an FDA inspector watching the line, compounded semaglutide is the same grain bill and recipe mixed in a licensed, inspected craft distillery. The whiskey in the glass can be functionally identical. The chain of custody and the scale of oversight are not.

The regulatory framework is different. The manufacturing oversight is different. The finished form is different. The excipients may differ depending on the pharmacy.

What is not different is the active ingredient itself, assuming it comes from a properly registered supplier and the pharmacy verifies identity and purity through its own testing.

The Shortage That Made Compounding Legal (and What Happened Next)

The FDA placed Wegovy on its drug shortage list in March 2022 and Ozempic in August 2022. Both shortages came down to demand swamping Novo Nordisk's manufacturing capacity. Under federal law, when a drug appears on the shortage list, 503A and 503B pharmacies may compound preparations that would otherwise be considered essentially copies of the FDA-approved product.

In October 2024 the FDA initially declared the semaglutide shortage resolved. That status was challenged in court, and the agency reissued guidance permitting continued compounding under specific circumstances, including demonstrated clinical need not met by the commercial product. The legal landscape keeps shifting. As of mid-2026, compounded semaglutide remains available through qualified providers working with licensed 503A and 503B compounding pharmacies, under clinical-need pathways that document patient-specific factors justifying the compounded preparation.

Here's why this matters if you're a patient: if you start compounded semaglutide, you should understand that the regulatory ground beneath you moves more than it does with a branded product. Ongoing access depends on continued legal availability of the compounding pathway. Good providers watch this closely and communicate changes proactively. Ask yours how they'd handle a sudden regulatory shift before you fill your first vial.

For a deeper look at the regulatory framework, see our supporting article on the 503A and 503B regulatory framework.

The Evidence Gap (and How Big It Actually Is)

The clinical trial evidence for semaglutide's weight-loss efficacy comes from trials of Wegovy, not compounded preparations. STEP-1 reported 14.9 percent mean weight loss at 2.4 mg over 68 weeks (Wilding et al., NEJM 2021). STEP-3 hit 16.0 percent when combined with intensive behavioral therapy (Wadden et al., JAMA 2021). STEP-4 demonstrated the importance of staying on therapy (Rubino et al., JAMA 2021). SELECT established cardiovascular risk reduction at the same dose (Lincoff et al., NEJM 2023).

Compounded semaglutide has not been studied in trials of that scale. It can't be, really, because "compounded semaglutide" isn't a single standardized product the way Wegovy is. It varies by pharmacy, by excipient, by lot. Patients on compounded preparations broadly report outcomes consistent with the published trial data when they're on equivalent doses and titration schedules, but published evidence for any specific compounded formulation is limited.

The boring truth is that this gap is simultaneously real and, for most patients, not clinically dramatic. If the molecule is the same and the dose is the same, the pharmacology predicts the same effect. But prediction is not proof, and patients who need the security of direct trial evidence backing their exact preparation should choose the branded product. Patients comfortable with the pharmacological reasoning, and who have a practical reason to prefer compounded (usually cost), can make a reasonable choice to go the other direction.

My own read, having watched this debate for three years: the evidence gap is a legitimate consideration, not a disqualifying one. It's roughly analogous to using a compounded thyroid preparation when brand-name levothyroxine is available. The same pharmacology applies. The same molecule is at work. The regulatory and evidentiary frameworks differ. Reasonable clinicians land on both sides.

Why People Go Compounded

Cost is the overwhelming driver. A patient without insurance coverage facing $1,349 a month for Wegovy, or a patient who checked every Wegovy coupon and savings card pathway and still can't get to a manageable number, is looking at compounded semaglutide at roughly $179 to $399 monthly through a reputable provider.

But cost isn't the only reason. Some patients have documented sensitivities to excipients in the branded pen. Some need a dose that falls between the fixed steps in the branded titration schedule. Some are on Medicare and currently excluded from Part D coverage of weight-loss medications under federal statute, which affects a significant population of older adults with obesity who are otherwise excellent candidates.

For more on cost, see our cluster hub on cost and access.

Why People Stay Branded

There are equally strong reasons to choose Wegovy or Ozempic when access and cost work.

If your commercial insurance covers Wegovy with a tolerable copay, the branded product is almost always the better pick. You're paying less out of pocket and getting the product backed by direct trial evidence. That's a hard combination to beat.

Some patients simply value the regulatory certainty. They want the FDA-approved finished product, manufactured by one company, tested to one standard, dispensed in a pre-filled pen that removes dosing guesswork. That's a legitimate preference, not a paranoid one.

Others have had inconsistent experiences with a compounded preparation (injection-site irritation, variable potency feel, lot-to-lot differences) and prefer the standardized pen-injector form. This is real. Some compounding pharmacies are more consistent than others, and the patient doesn't always have visibility into which is which.

Switching Between the Two

Switching in either direction is clinically straightforward when the dose stays the same. Same molecule, same pharmacology, no washout period needed. The switch dose goes on the regular weekly schedule.

The practical headaches are administrative: a new prescription written for the new product, possible insurance prior authorization if switching to branded, and a minor learning curve if you're going from pen to vial-and-syringe or vice versa.

For step-by-step switching guidance, see our supporting article on switching from Wegovy to compounded semaglutide.

Questions Worth Asking Before You Choose

Whether this is your first time or you're considering a switch, the list is the same:

What does my clinician specifically recommend for my situation, and why?

What's the total monthly cost, and does the price change after the first month? (Some providers run low introductory pricing that jumps later.)

What's the exact dose, concentration, and titration schedule?

Where is the medication being compounded, and is the pharmacy licensed in my state?

What's the plan if I have side effects, need a dose hold, or need to pause?

What lab work is happening before and during therapy?

What happens to my supply if the regulatory or shortage landscape changes for compounded preparations?

A good clinic will answer every one of these without hesitation. If your provider gets defensive at any of them, that's information too.

This hub is part of the Compounded Semaglutide vs Ozempic and Wegovy cluster. Related supporting articles include:

For the foundational overview, return to the pillar guide.

Not FDA-approved. HealthRX is not a medical practice. Information on this site is for educational purposes and is not a substitute for individualized medical advice. Treatment decisions are made between you and a licensed clinician. Compounded semaglutide is dispensed by state-licensed 503A pharmacies and FDA-registered 503B outsourcing facilities under individual prescriptions. Ozempic and Wegovy are registered trademarks of Novo Nordisk. References: STEP-1 (Wilding et al., NEJM 2021), STEP-3 (Wadden et al., JAMA 2021), STEP-4 (Rubino et al., JAMA 2021), SELECT (Lincoff et al., NEJM 2023), SUSTAIN program.